These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1665321)

  • 1. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro.
    Greenberg PD; Reusser P; Goodrich JM; Riddell SR
    Ann N Y Acad Sci; 1991 Dec; 636():184-95. PubMed ID: 1665321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.
    Riddell SR; Reusser P; Greenberg PD
    Rev Infect Dis; 1991; 13 Suppl 11():S966-73. PubMed ID: 1664137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
    N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
    Reusser P; Riddell SR; Meyers JD; Greenberg PD
    Blood; 1991 Sep; 78(5):1373-80. PubMed ID: 1652311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy.
    Vaz-Santiago J; Lulé J; Rohrlich P; Kravtzoff R; Le Roy E; Davignon JL; Betbeder D; Davrinche C
    Cytotherapy; 2002; 4(1):11-9. PubMed ID: 11953037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
    Lemmermann NA; Reddehase MJ
    Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones.
    Riddell SR; Walter BA; Gilbert MJ; Greenberg PD
    Bone Marrow Transplant; 1994; 14 Suppl 4():S78-84. PubMed ID: 7728132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
    Hobeika A; Osada T; Serra D; Peplinski S; Hanson K; Tanaka Y; Niedzwiecki D; Chao N; Rizzieri D; Lyerly H; Clay T; Morse M
    Cytotherapy; 2008; 10(3):289-302. PubMed ID: 18418774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
    Li CR; Greenberg PD; Gilbert MJ; Goodrich JM; Riddell SR
    Blood; 1994 Apr; 83(7):1971-9. PubMed ID: 8142663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
    Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
    Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus.
    Gilbert MJ; Riddell SR; Li CR; Greenberg PD
    J Virol; 1993 Jun; 67(6):3461-9. PubMed ID: 8388509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
    Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation.
    Boland GJ; Vlieger AM; Ververs C; De Gast GC
    Clin Exp Immunol; 1992 Jun; 88(3):506-11. PubMed ID: 1318805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
    Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
    Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease.
    Woo PC; Lo CY; Lo SK; Siau H; Peiris JS; Wong SS; Luk WK; Chan TM; Lim WW; Yuen KY
    Clin Diagn Lab Immunol; 1997 Sep; 4(5):515-8. PubMed ID: 9302197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
    Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.